Val-Cit-MMAF
A key ADC payload variant that pairs the protease-sensitive Val-Cit dipeptide linker with monomethyl auristatin F (MMAF), a polar microtubule inhibitor. The anionic C-terminal phenylalanine residue of MMAF confers reduced cell membrane permeability, limiting the cytotoxicity of free toxin to bystander cells. This bystander effect profile, combined with efficient cathepsin B-triggered release, makes the Val-Cit-MMAF construct particularly suitable for targeting solid tumors and antigens with heterogeneous expression, as exemplified by the ADC glembatumumab vedotin.
Similar Products: Val-Cit-MMAE
